Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.
AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval..
AstraZeneca plc (LON:AZN) has announced that the Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognised a favourable benefit risk profile for AstraZeneca and MSD’s Lynparza (olaparib)..
GSK plc (LON:GSK) has announced its 1st quarter results. Q1 2023 performance highlights: · Sales performance reflected lower COVID-19 solutions sales versus Q1 2022. Excluding COVID-19 solutions, sales grew +10%..
hVIVO plc (Euronext & LON:HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge..
GSK plc (LON/NYSE: GSK) has announced that the European Medicines Agency (EMA) validated the Company’s Type II Variation for a potential new indication for Jemperli (dostarlimab) in combination with chemotherapy..
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided a further update on its ongoing in vitro siRNA..
hVIVO plc (Euronext & LON:HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge..
Convatec Group Plc [LON:CTEC] has announced it has acquired the anti-infective nitric oxide technology platform of 30 Technology Limited which includes new product assets and research and development. In addition..
GSK plc (LON/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) has announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical company..
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its ongoing siRNA research work. The..
GSK plc (LON/NYSE: GSK) presented positive results from the pivotal EAGLE-2 and EAGLE-3 phase III trials for gepotidacin, an investigational, first-in-class oral antibiotic with a novel mechanism of action for..
AstraZeneca plc (LON:AZN), Swedish Orphan Biovitrum AB (publ) (Sobi) and Sanofi have updated and simplified their contractual arrangements relating to the development and commercialisation of nirsevimab in the US. Given..
hVIVO plc (Euronext / LON:HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge..
Miton UK MicroCap Trust plc (LON:MINI) Co-Fund Manager Gervais Williams was asked by DirectorsTalk his views on portfolio company Celadon Pharmaceuticals plc (LON:CEL) earlier this month. DirectorsTalk asked, “In the health..
Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary..
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided its audited results for the year ended 31 December..
Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a leading infectious disease focused biopharmaceutical company, has announced that further to its announcement on 4 October 2022, it has been granted a patent by..
Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a leading infectious disease focused biopharmaceutical company, has announced the data readout from the bacterial lipopolysaccharide (‘LPS’) human challenge trial for POLB 001, a..
Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of..
hVIVO plc (Euronext & LON:HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge..
